References
- Marks F, Klingmuller U, Muller-Decker K. Cellular signal processing. 2nd ed. New York: Garland Science; 2017.
- McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL. Advances in targeting signal transduction pathways. Oncotarget. 2012; 3:1505–21.
- Wilson J, Hunt T. Molecular biology of the cell. 6th ed. New York: Garland Science; 2015.
- Archbold HC, Yang YX, Chen L, Cadigan KM. How do they do Wnt they do?: regulation of transcription by the Wnt/β-catenin pathway. Acta Physiol (Oxf.). 2012; 204:74–109.
- Kafri P, Hasenson SE, Kanter I, Sheinberger J, Kinor N, Yunger S, Shav-Tal Y. Quantifying β-catenin subcellular dynamics and cyclin D1 mRNA transcription during Wnt signaling in single living cells. Elife. 2016; 5:e16748. doi: 10.7554/eLife.16748
- Jordan JD, Landau EM, Iyengar R. Signaling networks: the origins of cellular multitasking. Cell. 2000; 103:193–200.
- MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17:9–26.
- Donmez HG. β-Catenin in cervicovaginal smears during regular menstrual cycles. Asian Biomed (Res Rev News). 2020; 14:187–94.
- Zhang Z, Wang X, Zhang L, Shi Y, Wang J, Yan H. Wnt/β-catenin signaling pathway in trophoblasts and abnormal activation in preeclampsia. Mol Med Rep. 2017; 16:1007–13.
- Nguyen VHL, Hough R, Bernaudo S, Peng C. Wnt/β-catenin signalling in ovarian cancer: insights into its hyperactivation and function in tumorigenesis. J Ovarian Res. 2019; 12:122. doi: 10.1186/s13048-019-0596-z
- Katoh M, Katoh M. Molecular genetics and targeted therapy of WNT-related human diseases. Int J Mol Med. 2017; 40:587–606.
- Zhou Y, Wang T, Hamilton JL, Chen D. Wnt/β-catenin signaling in osteoarthritis and in other forms of arthritis. Curr Rheumatol Rep. 2017; 19:53. doi: 10.1007/s11926-017-0679-z
- Mercer KE, Hennings L, Ronis MJ. Alcohol consumption, Wnt/β-catenin signaling, and hepatocarcinogenesis. In: Vasiliou V, Zakhari S, Seitz H, Hoek J, editors. Biological basis of alcohol-induced cancer. Advances in Experimental Medicine and Biology, vol 815. Cham: Springer; 2015, p. 185–95.
- Chen N, Wang J. Wnt/β-Catenin signaling and obesity. Front Physiol. 2018; 9:792. doi: 10.3389/fphys.2018.00792
- Zhou L, Liu Y. Wnt/β-catenin signalling and podocyte dysfunction in proteinuric kidney disease. Nat Rev Nephrol. 2015; 11:535–45.
- Wu C, Zhuang Y, Jiang S, Liu S, Zhou J, Wu J, et al. Interaction between Wnt/β-catenin pathway and microRNAs regulates epithelial-mesenchymal transition in gastric cancer. Int J Oncol. 2016; 48:2236–46.
- Ghahhari NM, Babashah S. Interplay between microRNAs and WNT/β-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur J Cancer. 2015; 51:1638–49.
- Ashihara E, Takada T, Maekawa T. Targeting the canonical Wnt/β-catenin pathway in hematological malignancies. Cancer Sci. 2015; 106:665–71.
- Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev. 2018; 62:50–60.
- Ghosh N, Hossain U, Mandal A, Sil PC. The Wnt signaling pathway: a potential therapeutic target against cancer. Ann N Y Acad Sci. 2019; 1443:54–74.